Prevencio, Inc.

Blood test for ER patients with heart attack symptoms. Test determines whether patients can go home or needs more treatment. Saves money & improves outcomes.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Kirkland, WA, US
  • Currency USD
  • Founded 2006
  • Employees 3
  • Website prevenciomed.com

Company Summary

Prevencio® is an early-stage biotechnology venture that is currently conducting clinical studies in the early detection of coronary artery disease in the ER. Prevencio’s value proposition is to develop and market cost-effective diagnostic products for the unmet need of coronary artery disease for detection to “Rule In, Rule Out” The AHA reports that over 6 million patients annually present to the ER with symptoms associated with a heart attack.

Team

  • Gary Frank
    COO, Co-Founder

    • Over the last 22 years Gary H. Frank has been directly involved with medical and other companies to strengthen and enable their business strategies by raising early stage capital, mezzanine and second round financing, and by providing liquidity events by M&A and public offerings as well as implement turn-a-round strategies through his company, Global Ventures, LLC, Bellevue, WA. Mr. Frank has been a YPO (Young Presidents Organization) member.

  • Rhonda Rhryne, CEO

  • Robert Masterson, Ph.D. Diector
    Chief Commercial Officer

    Ph.D., Iowa State University; B.S., University of Washington.
    Previously: Tessera Diagnostics, Skin Biology, Q-pharma.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free